I can’t think of any large western pharmas that don’t now have a direct presence in China – Pfizer, Novartis, J & J, AbbVie, Roche, Sanofi, Astra Zeneca, BMS, Eli Lilly, Merck, Novo Nordisk, GSK, Bayer, Boehringer Ingelheim…. Astra Zeneca, for example, has Chinese sales revenue of US$6bn+ p.a.
Neuren filed patent applications for both its Compositions of Trofinetide and Methods and Compositions for Treatment of Rett Syndrome in China in 2020, so there would appear to be intention to market trofinetide in China.
https://patentscope.wipo.int/search/en/detail.jsf?docId=CN368036422&_cid=P20-LE6B2F-95444-1
https://patentscope.wipo.int/search/en/detail.jsf?docId=CN379891115&_fid=WO2021086892
On the subject of patents, Acadia filed a new patent application, Crystalline Forms of Trofinetide in late January, claiming a crystalline form of trofinetide that can be dissolved in water. This is said to be a more chemically stable solid form of trofinetide.
https://patentscope.wipo.int/search/en/detail.jsf?docId=US390987568&_cid=P20-LE6B2F-95444-1
I can’t think of any large western pharmas that don’t now have a...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.01 |
Change
-0.010(0.08%) |
Mkt cap ! $1.662B | |||
| Open | High | Low | Value | Volume |
| $13.06 | $13.26 | $12.81 | $5.865M | 451.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 14541 | $13.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.02 | 2438 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |